TUESDAY, SEPTEMBER 27, 2016

Thomson Reuters' ISP & Science division releases disease profile on Ebola

Thomson Reuters' Intellectual Property and Science division recently released a comprehensive disease profile on the Ebola virus that details new treatments and experimental drugs nearing development.

The Ebola outbreak in West Africa has caused more than 1,000 deaths in Sierra Leone, Liberia and Guinea. According to the World Health Organization, the fatality rate is approximately 90 percent, with no treatment currently available.

Two potential treatments, however, are in the pipeline-Sarepta Therapeutics and Tekmira are developing expression inhibitors, both of which are in Phase 1 clinical trials, to "disable" certain genes in the virus.

Two experimental approaches are also preparing to enter the drug pipeline. ZMapp, which is under development by Mapp BioPharmaceutical, LeafBio, the U.S. government and Public Health Agency of Canada (PHAC), is a mix of three antibodies to target the virus and halt the progression of the virus-the treatment has worked on two American healthcare workers infected by the outbreak in West Africa. Another treatment is a vaccine under development by China's Beijing Institute of Biotechnology.